Ipilimumab Immunotherapy (YERVOY) for Metastatic Melanoma , Cutaneous Melanoma & Advanced Renal Cell Carcinoma: Indication, Side Effects and Mechanism of Action
Ipilimumab (Yervoy) is FDA Approved Immune Check Point Inhibitors For Certain Cancers Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture. Indication of Ipilimumab (YERVOY) Ipilimumab (YERVOY) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Metastatic Melanoma - treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older). Cutaneous Melonama - adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. Advanced Renal Cell Carcinoma : Treatment of patients with intermediate or poor risk, previously untrea...